


Sparsentan (SPAR) as First-line Treatment of Incident Patients with IgA Nephropathy: Interim Analysis of the SPARTAN Trial



Sparsentan 200mg until week two and increased to 400mg thereafter



RAS I- Renin angiotensin system inhibitors, CR- complete remission of proteinuria < 0.3 g/d, U sCD/cr- Urinary soluble scavenger receptor differentiation antigen, IST- Immunosuppression

Komers et al.
VA by Priya John
@drpriyajohn

Conclusions: The interim findings of the SPARTAN trial show that SPAR as first-line treatment was generally well tolerated and reduced proteinuria $\approx 70\%$ over 24 week in newly diagnosed IgAN patients.

